Study Evaluating Venlafaxine ER in Recurrent Depression

Official Title: “An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER”

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

Intervention(s) in this Clinical Trial

• Drug: Venlafaxine ER

Inclusion Criteria

• Clinical diagnosis for recurrent major depression

Exclusion Criteria

• The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine
• ER during the current episode of major depression or the patient is treatment-resistant
• Known hypersensitivity to venlafaxine or fluoxetine
• History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry

Overall Clinical Trial Officials and Contacts

Medical Monitor, MD Study Director Wyeth is now a wholly owned subsidiary of Pfizer  

Information obtained from ClinicalTrials.gov on February 02, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00046020

Study ID Number: 0600B-100469

ClinicalTrials.gov Identifier: NCT00046020

Health Authority: United States: Food and Drug Administration